drugset / Trial / NCT05724576
Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will test the hypothesis intracoronary administration of OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells) just after finishing the primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients without cardiogenic shock is safe and may provide benefit on improving left ventricular ejection fraction (LVEF) during clinical follow-up.
Timeline
- Start
- 2023-06-26
- Primary completion
- 2026-05-18
- Completion
- 2026-05-18
Outcome
Outcome not reported
Stopped: “Sponsor's decision (No further development plan for this investigational product)”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OmniMSC-AMI | Cell therapy | 1.5e+07 cells | Other |
| Subject | OmniMSC-AMI | Cell therapy | 3e+07 cells | Other |
Indications
No indication recorded.